VIDEO: ONL1204 slows geographic atrophy lesion growth in phase 1b study
In this Healio Video Perspective from the ASRS meeting, Durga Borkar, MD, of Duke University Eye Center presents data from a phase 1b study investigating ONL1204, a Fas inhibitor, for geographic atrophy.
According to Borkar, the study had two components: an open-label dose-escalation study in which participants received one intravitreal injection of ONL1204 and a natural history and treatment portion in which GA lesion growth was monitored for 6 months before patients were randomly assigned to receive low-dose ONL1204, high-dose ONL1204 or sham.
The results were “very exciting and encouraging,” Borkar said, with ONL1204 demonstrating a reduction in the rate of GA lesion growth in both components of the study.
Collapse
Borkar D. Fas inhibition with ONL1204 for the treatment of geographic atrophy: First-time results from a phase 1b study. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about